Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PainchekASX:PCK +9.52%48 EV-to-EBITDA is -1.85 as of Jul. 16, 2026. GuruFocus rates ASX:PCK with a GF Score™ of 48/100 and a GF Value™ of A$0.40 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 507 Healthcare Providers & Services companies, Painchek ranks worse than 197238.46% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Painchek's enterprise value is A$17.16 Mil.
Painchek's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-9.30 Mil. Therefore, Painchek's EV-to-EBITDA for today is -1.85.
The historical rank and industry rank for Painchek's EV-to-EBITDA or its related term are showing as below:
ASX:PCK'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -66.56 Med: -4.68 Max: -1.73
Current: -1.85
During the past 13 years, the highest EV-to-EBITDA of Painchek was -1.73. The lowest was -66.56. And the median was -4.68.
ASX:PCK's EV-to-EBITDA is ranked worse than 100% of 507
companies
in the Healthcare Providers & Services industry
Industry Median: 11.03
vs ASX:PCK: -1.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Painchek (ASX:PCK) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Painchek's share price for today is A$0.115.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Painchek's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.047.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Painchek's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PCK vs VEEV, BTSG, TEM: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Painchek's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Painchek EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Painchek's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Painchek's EV-to-EBITDA falls into.
Painchek's current Enterprise Value is A$17.16 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Painchek's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-9.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Painchek (ASX:PCK) has a EV-to-EBITDA of -1.85 as of Jul. 16, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Painchek. According to the industry distribution chart, Painchek ranks #999999 out of 507 companies in the Healthcare Providers & Services industry.
Is Painchek's EV-to-EBITDA too high?
Painchek's current EV-to-EBITDA is -1.85. Based on the distribution chart, Painchek ranks #999999 out of 507 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Painchek has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #999999 out of 507 companies for EV-to-EBITDA. This places Painchek in the lower half of its industry. The industry median EV-to-EBITDA is 11.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 11.03, based on 507 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Painchek. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 11.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current EV-to-EBITDA is -1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.12 — trading 71.3% below its estimated fair value. The current EV-to-EBITDA is -1.85. Painchek's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Painchek (ASX:PCK), the current EV-to-EBITDA is -1.85 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Painchek (ASX:PCK) Overvalued in 2026?
Based on GuruFocus' analysis, Painchek stock appears to be undervalued.
The current stock price of A$0.12 is trading 71.3% below its estimated GF Value™ of A$0.40.
GuruFocus considers Painchek to be Possible Value Trap.
Key valuation signals for ASX:PCK:
EV-to-EBITDA: -1.85
GF Value™: A$0.40 vs. price of A$0.12 (71.3% below fair value)
No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
48GF Score
Get the complete analysis for ASX:PCK
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PCK has been successfully added to your 
